Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer

Thyroid

Volumn 25, Issue 6, 2015, Pages 681-687

  Marti, Jennifer L ^a   Jain, Kunal S ^b   Morris, Luc G T ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SALIVARY GLAND CANCER; SECOND CANCER; SURVIVAL TIME; YOUNG ADULT; CANCER REGISTRY; FEMALE; INCIDENCE; KIDNEY NEOPLASMS; LEUKEMIA; MALE; NEOPLASMS, SECOND PRIMARY; PRESCHOOL CHILD; REGISTER; SALIVARY GLAND NEOPLASMS; THYROID NEOPLASMS; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; LEUKEMIA; MALE; NEOPLASMS, SECOND PRIMARY; REGISTRIES; SALIVARY GLAND NEOPLASMS; SEER PROGRAM; THYROID NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 84930518872     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0067     Document Type: Article

References (30)

1. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE 2009 Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 156:167-172.
2. Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB 2010 Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34: 1192-1202.
3. Enomoto Y, Enomoto K, Uchino S, Shibuya H, Watanabe S, Noguchi S 2012 Clinical features, treatment, and longterm outcome of papillary thyroid cancer in children and adolescents without radiation exposure. World J Surg 36: 1241-1246.
4. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S 2006 Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 243:525-532.
5. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B 2007 Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 48:879-888.
6. Shapiro NL, Bhattacharyya N 2005 Population-based outcomes for pediatric thyroid carcinoma. Laryngoscope 115: 337-340.
7. Newman KD, Black T, Heller G, Azizkhan RG, Holcomb GW, 3rd, Sklar C, Vlamis V, Haase GM, La Quaglia MP 1998 Differentiated thyroid cancer: determinants of disease progression in patients
8. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL 1998 Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 49:619-628.
9. Hebestreit H, Biko J, Drozd V, Demidchik Y, Burkhardt A, Trusen A, Beer M, Reiners C 2011 Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. Eur J Nucl Med Mol Imaging 38:1683-1690.
10. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644.
11. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with lowrisk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439-4446.
12. Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, Schwartz SM, Bernstein L, Chen VW, Goodman MT, Gomez SL, Graff JJ, Lynch CF, Lin CC, Edwards BK 2007 Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 18:177-187.
13. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF 2002 Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 94: 1537-1545.
14. Clegg LX, Gail MH, Feuer EJ 2002 Estimating the variance of disease-prevalence estimates from population-based registries. Biometrics 58:684-688.
15. Zippin C, Lum D, Hankey BF 1995 Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76:2343-2350.
16. Warren S GO 1932 Multiple primary malignant tumors: a survey of the literature and a statistical study. Cancer 16: 1358-1414.
17. Curtis RE, Ries LA 1973 Methods. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF (eds) New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, Bethesda, MD.
18. Schoenberg BS, Myers MH 1977 Statistical methods for studying multiple primary malignant neoplasms. Cancer 40: 1892-1898.
19. Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP 1995 Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol 142:653-665.
20. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF (eds) 2006 New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000.NationalCancer Institute, Bethesda, MD.
21. Brenner DJ, Hall EJ 2007 Computed tomography-an increasing source of radiation exposure. N Engl J Med 357: 2277-2284.
22. Brenner D, Elliston C, Hall E, Berdon W 2001 Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 176:289-296.
23. Chodick G, Ronckers CM, Shalev V, Ron E 2007 Excess lifetime cancer mortality risk attributable to radiation exposure from computed tomography examinations in children. Isr Med Assoc J 9:584-587.
24. Dohan O, Carrasco N 2003 Advances in Na(\+)/I() symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59-70.
25. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515.
26. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
27. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and metaanalysis. Thyroid 19:451-457.
28. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM 2007 Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17:1277-1288.
29. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L 1997 Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 38:669-675.
30. Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Mang O, Lau WH 2004 Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer 42:176-183.